Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
BioNexus Gene Lab Corp. (BGLC) had Debt to Equity Ratio of 0.01 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$9.51M |
|
$-1.60M |
|
$8.22M |
|
$1.29M |
|
$11.08M |
|
$-1.57M |
|
$-0.02M |
|
$-1.59M |
|
$-1.59M |
|
$-1.60M |
|
$-1.60M |
|
$-1.60M |
|
$-1.60M |
|
$-1.43M |
|
$-1.27M |
|
17.82M |
|
17.82M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$7.43M |
|
$1.52M |
|
$3.00M |
|
$10.43M |
|
$1.95M |
|
-- |
|
$0.16M |
|
$2.11M |
|
$8.32M |
|
$8.32M |
|
$8.32M |
|
17.97M |
|
| Cash Flow Statement Financials | |
$-2.23M |
|
$0.42M |
|
$0.14M |
|
$4.52M |
|
$2.89M |
|
$-1.63M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.81 |
|
-- |
|
-- |
|
-- |
|
|
Debt to Equity Ratio |
0.01 |
13.56% |
|
-16.55% |
|
-14.99% |
|
-13.38% |
|
-16.77% |
|
-16.81% |
|
$-2.46M |
|
-- |
|
-- |
|
-- |
|
0.91 |
|
5.92 |
|
5.71 |
|
63.88 |
|
-19.20% |
|
-19.20% |
|
-15.32% |
|
-19.20% |
|
$0.46 |
|
$-0.14 |
|
$-0.13 |
|